Catalyzing Growth in the Global Breast Cancer Therapeutics Market by insights10 - HTML preview

/ Home / Free Previews / Catalyzing Growth in the Global Breast Cancer Therapeutics Market

PLEASE NOTE: This is an HTML preview only and some elements such as links or page numbers may be incorrect.
Download the book in PDF, ePub, Kindle for a complete version.

GLOBAL

BREAST

CANCER

THERAPEUTICS MARKET

ANALYSIS, 2022-2030

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

CONTENTS

1. Overview

2. Prevalence of Breast Cancer in the World

3. Types of Breast Cancer

4. Drugs Approved for Breast Cancer

5. Market Size and Key Findings

6. Regional Analysis

7. Market Dynamics

8. Competitive Landscape

9. Healthcare Policy and Regulatory Landscape

10. Reimbursement Scenario

11. Latest Trends and Innovations

12. Conclusion

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Overview

The Global Breast Cancer Therapeutics Market is projected to grow from $18.2 Bn in 2022 to $48.0 Bn by 2030, registering a CAGR of 12.9% during the forecast period of 2022 - 2030.

Breast cancer is the second most common cancer in women worldwide, after skin cancer. The global breast cancer therapeutics market is a rapidly growing market and is expected to continue to grow in the coming years.

The market for breast cancer therapeutics is driven by a number of factors, including the increasing prevalence of breast cancer, the development of new and innovative drugs, and the growing demand for personalized medicine. The market is also benefiting from several initiatives and campaigns to raise awareness about breast cancer and the importance of early detection and treatment.

Some of the key players in the breast cancer therapeutics market include AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly. These companies are investing heavily in research and development to develop new treatments and improve existing ones. They are also working to improve patient access to breast cancer treatments by expanding their distribution networks and working with healthcare providers to improve diagnosis and treatment.

The breast cancer therapeutics market is segmented by type of therapy, including chemotherapy, targeted therapy, hormonal therapy, and others. The market is also segmented by types, distribution channels and regions.

Overall, the global breast cancer therapeutics market is expected to continue to grow at a rapid pace in the coming years, driven by increasing demand for effective treatments and ongoing investment in research and development.

Global Breast Cancer Therapeutics Market (in $ Bn) Matket is forecast to grow at a CAGR of 12.9%

48.0

42.6

37.7

33.4

29.8

26.2

23.2

20.5

18.2

2022

2023F

2024F

2025F

2026F

2027F

2028F

2029F

2023F

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

What is the Prevalence of

Breast Cancer in the World?

With 1 in 8 cancer diagnoses worldwide, breast cancer is the most frequently diagnosed cancer kind. Each year, there are more than 2.3 Mn new instances of breast cancer in the world, and there were also approximately 685,000 deaths from this illness, with significant regional variances between different nations and global areas.

Breast cancer is the primary or secondary cause of mortality for women from cancer in 95% of the world's nations. However, there are significant disparities in breast cancer survival between and within nations. Nearly 80% of breast and cervical cancer fatalities take place in low- and middle-income nations.

The most significant risk factor is age, and the oldest females have the highest age-specific incidence rates. Less than one in five women with breast cancer is diagnosed before the age of 50 in the UK, while more than one-third of cases affect women beyond the age of 70. In contrast, more than half of breast cancer cases in women under 50 years old occur in less developed nations.

These disparities in breast cancer incidence and survival are likely due to a number of factors, including access to healthcare, screening programs, and awareness of the signs and symptoms of breast cancer. In many low- and middle-income countries, women do not have regular access to healthcare, and screening programs for breast cancer are not widely available. As a result, breast cancer is often diagnosed at a later stage, when it is more difficult to treat and less likely to be cured.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Estimated new cancer cases and deaths by sex, US, 2023

Estimated New Cases

Estimated Deaths

Cancer Site

Both Sexes

Male

Female Both Sexes

Male

Female

All sites

1,958,310 1,010,310 948,000

609,820

322,080

287,740

Breast

300,590

2800

297,790

43,700

530

43,170

Oral cavity & pharynx

54,540

39,290

15,250

11,580

8140

3440

Tongue

18,040

13,180

4860

2940

1950

990

Mouth

14,820

8680

6140

3090

1870

1220

Pharynx

20,070

16,340

3730

4140

3260

880

Other oral cavity

1610

1090

520

1410

1060

350

Digestive system

348,840

194,980

153,860

172,010

99,350

72,660

Esophagus

21,560

17,030

4530

16,120

12,920

3200

Stomach

26,500

15,930

10,570

11,130

6690

4440

Small intestine

12,070

6580

5490

2070

1170

900

Colon & rectum

153,020

81,860

71,160

52,550

28,470

24,080

Colon

106,970

54,420

52,550

Rectum

46,050

27,440

18,610

Anus, anal canal, & anorectum

9760

3180

6580

1870

860

1010

Liver & intrahepatic bile duct

41,210

27,980

13,230

29,380

19,000

10,380

Gallbladder & other biliary

12,220

5750

6470

4510

1900

2610

Pancreas

64,050

33,130

30,920

50,550

26,620

23,930

Other digestive organs

8450

3540

4910

3830

1720

2110

Respiratory system

256,290

131,150

125,140

132,330

71,170

61,160

Larynx

12,380

9900

2480

3820

3070

750

Lung & bronchus

238,340

117,550

120,790

127,070

67,160

59,910

Other respiratory organs

5570

3700

1870

1440

940

500

Bones & joints

3970

2160

1810

2140

1200

940

Soft tissue (including heart)

13,400

7400

6000

5140

2720

2420

Skin (excluding basal & squamous)

104,930

62,810

42,120

12,470

8480

3990

Melanoma of the skin

97,610

58,120

39,490

7990

5420

2570

Other nonepithelial skin

7320

4690

2630

4480

3060

1420

Genital system

414,350

299,540

114,810

69,660

35,640

34,020

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Uterine cervix

13,960

4310

Uterine corpus

66,200

13,030

Ovary

19,710

13,270

Vulva

6470

1670

Vagina & other female genital

8470

1740

Prostate

288,300

34,700

Testis

9190

470

Penis & other male genital

2050

470

Urinary system

168,560

117,590

50,970

32,590

22,680

9910

Urinary bladder

82,290

62,420

19,870

16,710

12,160

4550

Kidney & renal pelvis

81,800

52,360

29,440

14,890

9920

4970

Ureter & other urinary organs

4470

2810

1660

990

600

390

Eye & orbit

3490

1900

1590

430

240

190

Brain & other nervous system

24,810

14,280

10,530

18,990

11,020

7970

Endocrine system

47,230

14,340

32,890

3240

1560

1680

Thyroid

43,720

12,540

31,180

2120

970

1150

Other endocrine

3510

1800

1710

1120

590

530

Lymphoma

89,380

49,730

39,650

21,080

12,320

8760

Hodgkin lymphoma

8830

4850

3980

900

540

360

Non‐Hodgkin lymphoma

80,550

44,880

35,670

20,180

11,780

8400

Myeloma

35,730

19,860

15,870

12,590

7000

5590

Leukemia

59,610

35,670

23,940

23,710

13,900

9810

Acute lymphocytic leukemia

6540

3660

2880

1390

700

690

Chronic lymphocytic leukemia

18,740

12,130

6610

4490

2830

1660

Acute myeloid leukemia

20,380

11,410

8970

11,310

6440

4870

Chronic myeloid leukemia

8930

5190

3740

1310

780

530

Other leukemia

5020

3280

1740

5210

3150

2060

Other & unspecified primary sites

32,590

16,810

15,780

48,160

26,130

22,030

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Depicts The Most Common Cancers Diagnosed in Men & Women In 2023

Estimated New Cases

Prostate

288,300

29%

Males

Females

Breast

297,790

31%

Lung & bronchus

117,550

12%

Lung & bronchus

120,790

13%

Colon & rectum

81,860

Colon & rectum

71,160

Urinary bladder

62,420

Uterine corpus

66,200

Melanoma of the skin

58,120

Melanoma of the skin

39,490

Kidney & renal pelvis

52,360

Non-Hodgkin hymphoma

35,670

Non-Godgkin lymphoma

44,880

Thyroid

31,180

Oral cavity & pharynx

39,290

Pancreas

30,920

Leukemia

35,670

Kidney & renal pelvis

29,440

Pancreas

33,130

Leukemia

23,940

All sites

1,010,310

100%

All Sites

948,000

100%

Estimated Deaths

Lung & bronchus

67,160

21%

Males

Females

Prostate

Lung & bronchus

34,700

59,910

21%

11%

Colon & rectum

Breast

28,470

43,170

15%

Pancreas

Colon & rectum

26,620

24,080

Liver & intrahepatic bile duct

Pancreas

19,000

23,930

Leukemia

Ovary

13,900

13,270

Esophagus

Uterine corpus

12,920

13,030

Urinary bladder

Liver & intrahepatic bile duct

12,160

10,380

Non-Hodgkin lymphoma

Leukemia

11,780

9,810

Brain & other nervous system

Non-Hodgkin lymphoma

11,020

8,400

All sites

Brain & other nervous system

322,080

7,970

100%

All sites

287,740

100%

Nearly half (48%) of all incident instances of cancer in males are for the prostate, lung and bronchus (hereafter lung), and colorectal cancers (CRCs), with 29% of diagnoses coming from prostate cancer alone.

Breast cancer alone accounts for 31% of all cancer diagnoses in women, whereas lung cancer, CRC, and breast cancer together account for 52% of all new diagnoses.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Types of

Breast Cancer?

There are several types of breast cancer, which are characterized based on the specific cells and tissues where the cancerous growth originates. The most common types of breast cancer are: Invasive Ductal Carcinoma (IDC)

Ductal Carcinoma in Situ (DCIS)

Invasive Lobular Carcinoma (ILC)

Triple-negative Breast Cancer (TNBC)

Metastatic Breast Cancer

Tubular Breast Cancer

Mucinous Breast Cancer

Inflammatory Breast Cancer (IBC)

Medullary Breast Cancer

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Ductal Carcinoma in Situ (DCIS):

DCIS is a non-invasive form of breast cancer that develops in the milk ducts of the breast. It is considered a pre-cancerous condition, as the abnormal cells are confined to the ducts and have not spread to nearby tissue.

In the US now, DCIS accounts for 20% to 25% of breast cancer diagnoses. This has increased along with the introduction of screening mammography because a sizable portion of DCIS is initially discovered on screening mammography. DCIS made up fewer than 5% of newly diagnosed breast cancers during the pre-screening mammography period.

Treatments available for Ductal Carcinoma in Situ (DCIS):

▪ Breast-conserving surgery (BCS)

▪ Mastectomy

▪ Hormone therapy after breast surgery

Distribution of new DCIS type breast cancer cases in the US

BY age group

20-34 Years

34-44 Years

45-54 Years

54-64 Years

64-74 Years

75-84 Years

85 Years & older

10%

28%

27%

21%

11%

Invasive Ductal Carcinoma (IDC):

IDC is the most common type of breast cancer, accounting for approximately 80% of all cases. It begins in the milk ducts of the breast but then invades the surrounding breast tissue.

Treatment for invasive ductal carcinoma

Invasive ductal carcinoma may be treated with:

▪

Surgery:

▪

Hormonal Therapy

▪

Radiation Therapy:

▪

Targeted Therapy

▪

Chemotherapy:

▪

Immunotherapy

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Estimated New Invasive Breast Cancer Cases among Women by Age, US, 2019

Age

Numbers

<40

11,870

40-49

37,150

50-59

61,560

60-69

74,820

70-79

52,810

79<

30,390

Invasive Lobular Carcinoma (ILC):

ILC originates in the lobules of the breast, which produce milk. It is less common than IDC, accounting for about 10-15% of all breast cancers. Treatment options may include surgery, radiation therapy, chemotherapy, and hormonal therapy.

Inflammatory Breast Cancer (IBC):

IBC is a rare and aggressive form of breast cancer that typically presents as a red, swollen, and warm breast. It occurs when cancer cells block the lymphatic vessels in the skin of the breast. Treatment for IBC usually involves a combination of different therapies, including Chemotherapy, Surgery, Radiation therapy, Targeted therapy, and Hormone therapy.

Triple-negative Breast Cancer (TNBC):

TNBC is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2/neu.

This means that the cancer does not respond to hormonal therapy or targeted therapies that are effective for other types of breast cancer. Treatment options may include surgery, radiation therapy, chemotherapy, and targeted therapy.

Lobular Carcinoma in Situ (LCIS):

When abnormal cells are discovered in the breast lobules, it is known as lobular carcinoma in situ (LCIS). The breast tissue around the lobules is not affected by the atypical cells.

Metastatic Breast Cancer:

Stage 4 breast cancer sometimes refers to metastatic breast cancer. Other body parts are now affected by the malignancy. Usually, the liver, bones, brain, and lungs are included in this.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

There are other types that are less commonly seen-Medullary Carcinoma:

Medullary carcinoma accounts for 3-5% of all breast cancer types. While the tumour frequently appears on mammography, it is not always felt as a bump. It can occasionally resemble a spongy breast tissue alteration.

Tubular Carcinoma:

Tubular carcinoma cells, which account for around 2% of all breast cancer diagnoses, have a recognisable tubular form. A clump of cells that can feel more like a spongy patch of breast tissue than a lump is typically discovered by a mammography. This particular kind of breast cancer typically affects women over the age of 50 and responds favourably to hormone therapy.

Mucinous Carcinoma (Colloid):

A percentage of breast tumours between 1% and 2% is mucinous carcinomas. Mucus production and poorly defined cells are the major characteristics that set them apart from one another. It typically has a good prognosis as well.

Paget Disease of The Breast or Nipple:

A uncommon kind of cancer, breast Paget disease affects the skin of the nipple and frequently the areola, the darker circle of skin surrounding the nipple. Most persons with Paget disease that is visible on the nipple also have one or more tumours inside the same breast, which are often either invasive breast cancer or ductal carcinoma in situ (1–3). The initial signs of Paget illness are usually misdiagnosed because they are easily mistaken for more wide-spread skin disorders that affect the nipple. The prognosis for Paget disease, like all breast cancers, depends on a number of variables, such as the existence or absence of invasive malignancy and whether or not it has spread to neighbouring lymph nodes.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

What are the treatment options

for Breast Cancer?

The treatment of breast cancer has made remarkable strides in recent years, offering a beacon of hope to those affected by this pervasive disease. Breast cancer treatment is not a one-size-fits-all approach but rather a finely tuned orchestra of therapies tailored to the specific type, stage, and individual characteristics of the cancer. From surgical procedures designed to remove or reshape affected breast tissue to targeted therapies aimed at disrupt-ing the molecular mechanisms of cancer growth, the landscape of breast cancer treatment is as diverse as it is dynamic.

This comprehensive approach encompasses the traditional pillars of surgery, chemotherapy, and radiation therapy, as well as the latest innovations in immunotherapy and precision medicine. With a better understanding of these multifaceted treatment options, patients and healthcare providers alike can navigate the complex journey towards defeating breast cancer with increased confidence and optimism.

Drugs Approved to Prevent Breast Cancer

▪

Evista (Raloxifene Hydrochloride)

▪

Soltamox (Tamoxifen Citrate)

▪

Raloxifene Hydrochloride

▪

Tamoxifen Citrate

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Drugs Approved to Treat Breast Cancer

▪

Abemaciclib

▪

Letrozole

▪

Abraxane (Paclitaxel Albumin-stabilized

▪

Lynparza (Olaparib)

Nanoparticle Formulation)

▪

Margenza (Margetuximab-cmkb)

▪

Ado-Trastuzumab Emtansine

▪

Margetuximab-cmkb

▪

Afinitor (Everolimus)

▪

Megestrol Acetate

▪

Afinitor Disperz (Everolimus)

▪

Methotrexate Sodium

▪

Alpelisib

▪

Neratinib Maleate

▪

Anastrozole

▪

Nerlynx (Neratinib Maleate)

▪

Aredia (Pamidronate Disodium)

▪

Olaparib

▪

Arimidex (Anastrozole)

▪

Orserdu (Elacestrant Dihydrochloride)

▪

Aromasin (Exemestane)

▪

Paclitaxel

▪

Capecitabine

▪

Paclitaxel Albumin-stabilized Nanoparticle

▪

Cyclophosphamide

Formulation

▪

Docetaxel

▪

Palbociclib

▪

Doxorubicin Hydrochloride

▪

Pamidronate Disodium

▪

Elacestrant Dihydrochloride

▪

Pembrolizumab

▪

Ellence (Epirubicin Hydrochloride)

▪

Perjeta (Pertuzumab)

▪

Enhertu (Fam-Trastuzumab Deruxtecan-nx-

▪

Pertuzumab

ki)

▪

Pertuzumab, Trastuzumab, and Hyaluroni-

▪

Epirubicin Hydrochloride

dase-zzxf

▪

Eribulin Mesylate

▪

Phesgo (Pertuzumab, Trastuzumab, and

▪

Everolimus

Hyaluronidase-zzxf)

▪

Exemestane

▪

Piqray (Alpelisib)

▪

5-FU (Fluorouracil Injection)

▪

Ribociclib

▪

Fam-Trastuzumab Deruxtecan-nxki

▪

Sacituzumab Govitecan-hziy

▪

Fareston (Toremifene)

▪

Soltamox (Tamoxifen Citrate)

▪

Faslodex (Fulvestrant)

▪

Talazoparib Tosylate

▪

Femara (Letrozole)

▪

Talzenna (Talazoparib Tosylate)

▪

Fluorouracil Injection

▪

Tamoxifen Citrate

▪

Fulvestrant

▪

Taxotere (Docetaxel)

▪

Gemcitabine Hydrochloride

▪

Tecentriq (Atezolizumab)

▪

Gemzar (Gemcitabine Hydrochloride)

▪

Tepadina (Thiotepa)

▪

Goserelin Acetate

▪

Thiotepa

▪

Halaven (Eribulin Mesylate)

▪

Toremifene

▪

Herceptin Hylecta (Trastuzumab and

▪

Trastuzumab

Hyaluronidase-oysk)

▪

Trastuzumab and Hyaluronidase-oysk

▪

Herceptin (Trastuzumab)

▪

Trexall (Methotrexate Sodium)

▪

Ibrance (Palbociclib)

▪

Trodelvy (Sacituzumab Govitecan-hziy)

▪

Infugem (Gemcitabine Hydrochloride)

▪

Tucatinib

▪

Ixabepilone

▪

Tukysa (Tucatinib)

▪

Ixempra (Ixabepilone)

▪

Tykerb (Lapatinib Ditosylate)

▪

Kadcyla (Ado-Trastuzumab Emtansine)

▪

Verzenio (Abemaciclib)

▪

Keytruda (Pembrolizumab)

▪

Vinblastine Sulfate

▪

Kisqali (Ribociclib)

▪

Xeloda (Capecitabine)

▪

Lapatinib Ditosylate

▪

Zoladex (Goserelin Acetate)

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Drug Combinations Used in Breast Cancer

▪

CMF

▪

AC-T

▪

FEC

▪

CAF

▪

TAC

Below is a summary of some of the drugs commonly used to treat breast cancer:

▪

Hormone therapy: This type of therapy is used for hormone receptor-positive breast cancers and includes drugs that block the effects of estrogen on the cancer cells. Examples of hormone therapy drugs include tamox-ifen, aromatase inhibitors (such as letrozole, anastrozole, and exemestane), and fulvestrant.

▪

Chemotherapy: Chemotherapy is a systemic treatment that can be used to treat various types and stages of breast cancer. Examples of chemotherapy drugs used to treat breast cancer include taxanes (such as paclitaxel and docetaxel), anthracyclines (such as doxorubicin and epirubicin), and cyclophosphamide.

▪

Targeted therapy: Targeted therapy drugs are designed to attack specific proteins or genes in cancer cells.

Examples of targeted therapy drugs used to treat breast cancer include trastuzumab, pertuzumab, lapatinib, neratinib, and everolimus.

▪

Immunotherapy: Immunotherapy drugs work by stimulating the body's immune system to recognize and attack cancer cells. For breast cancer, the immunotherapy drug atezolizumab is sometimes used in combination with chemotherapy for triple-negative breast cancer that is PD-L1 positive.

▪

PARP inhibitors: PARP inhibitors are a type of targeted therapy drug that work by blocking an enzyme involved in DNA repair. These drugs are used to treat BRCA-mutated breast cancer and include olaparib, talazoparib, and rucaparib.

▪

Bisphosphonates and denosumab: These drugs are used to help prevent bone loss and reduce the risk of bone metastases in breast cancer patients. Examples of bisphosphonates include zoledronic acid and pamid-ronate, while denosumab is a monoclonal antibody.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

How big is the market for breast

cancer treatments, & what

are the key trends?

Market Size and Key Findings

Breast Cancer Therapeutics

Market Size, By Region

(in $ Bn)

3.822

9.1

3.458

APAC

Europe

Middle East

Africa

Latin America

North America

0.728

0.273

0.819

The data presented is tentative & subject to change in the final report.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Regional Analysis

The Global Breast Cancer Therapeutics Market is categorized into five regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global breast cancer drugs market in 2022 and is expected to remain dominant during the forecast period. This growth can be attributed to the presence of well-established corporations in the area, leading to the introduction of new treatments. Other contributing factors include the high incidence of breast cancer, a rising number of R&D

clinical trials for breast cancer therapies, and increasing acceptance of cutting-edge medicines.

For instance, the American Cancer Society predicted that there would be about 276,480 new cases of invasive breast cancer in women in the United States in 2020.

Due to the rising incidence of breast cancer and increased use of cutting-edge therapies in the region, Europe is anticipated to be the second-most prominent region throughout the projection period. For instance, female breast cancer is the most prevalent cancer diagnosed in Europe, according to figures provided by the Joint Research Center (JRC) of the European Union. In the EU-27, it was predicted that more than 355,000 women would receive a breast cancer diagnosis in 2020.

The region with the biggest growth is expected to be Asia Pacific, which will benefit from rising patient populations, advanced medicine demand, and considerable increases in healthcare spending. For instance, F. Hoffmann-La Roche Ltd. announced the arrival of atezolizumab, an immunotherapy medicine, in India in April 2020 for the treatment of metastatic triple-negative breast cancer (TNBC).

In 2019, the Middle East and Africa's and Latin America's emerging markets contributed a considerably smaller contribution. But because of the increased presence of well-known firms in the regions, rising healthcare costs, soaring patient population, and high demand for sophisticated therapies, they are predicted to rise significantly over the course of the projection year.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Breast Cancer Therapeutics Market Size, By Countries (in $ Bn) Country

2022

CAGR

2030F

764.4

10.9%

1748.9

China

146.3

14.4%

429.2

Canada

145.6

12.9%

384.3

Japan

113.1

13.4%

309.4

Germany

66.6

11.1%

154.6

France

50.1

11.9%

123.0

47.3

10.9%

108.3

Brazil

45.5

13.9%

128.9

Italy

43.7

12.4%

111.3

Spain

35.1

11.9%

86.4

India

33.1

15.9%

107.8

Saudi Arabia

30.9

14.4%

90.8

South Korea

26.6

13.9%

75.3

Australia

21.8

14.4%

64.1

Turkey

14.6

13.4%

39.8

UAE

9.1

13.9%

25.8

Egypt

5.1

14.4%

14.9

Hong Kong

2.9

13.9%

8.3

Russia

29.7

Mexico

27.3

South Africa

11.8

Indonesia

10.9

Poland

10.6

Vietnam

9.1

Austria

7.3

Kuwait

7.3

Qatar

7.3

Sweden

6.6

Portugal

5.5

Romania

5.3

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Netherlands

4.7

Philippines

4.0

Finland

3.8

Algeria

3.6

Malaysia

2.9

Morocco

2.4

Singapore

2.2

Nigeria

1.6

Thailand

New Zealand

Ireland

Norway

Denmark

Belgium

Ukraine

Bulgaria

Venezuela

Senegal

Switzerland

Lebanon

Kenya

Libya

Tanzania

Argentina

Ecuador

For Country Specific Breast Cancer Therapeutics Report Click here 18

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Estimated age-standardized incidence rates (World) in 2020, breast, all ages

ASR (World) per 100 00

≥ 69.2

53.0-69.2

41.1-53.0

30.3-41.1

Not applicable

< 30.3

No data

Estimated age-standardized mortality rates (World) in 2020, breast, all ages

ASR (World) per 100 00

≥ 19.4

16.6 - 19.4

13.8 - 16.6

11.5 - 13.8

Not applicable

< 11.5

No data

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Market Dynamics

What are the key drivers of the Global Breast Cancer Therapeutics Market?

The global breast cancer therapeutics market is driven by several factors, including: Increasing incidence of breast cancer: The incidence of breast cancer is on the rise globally, with an increasing number of women being diagnosed with the disease each year. This has resulted in a growing demand for effective treatments for breast cancer, which is driving the growth of the breast cancer therapeutics market.

Development of new and innovative drugs: There has been significant investment in research and development to develop new and innovative drugs for the treatment of breast cancer. These new drugs have been shown to be more effective and less toxic than traditional chemotherapy, and they are driving the growth of the breast cancer therapeutics market.

Growing demand for personalized medicine: Personalized medicine is becoming increasingly important in the treatment of breast cancer. This involves tailoring treatments to the specific genetic makeup of the patient, which can result in more effective treatments and fewer side effects. The growing demand for personalized medicine is driving the growth of the breast cancer therapeutics market.

Increasing healthcare expenditure: Healthcare expenditure is increasing globally, and this is leading to increased investment in the development and distribution of breast cancer therapeutics. This is driving the growth of the breast cancer therapeutics market.

Awareness and education initiatives: There are many initiatives and campaigns aimed at raising awareness about breast cancer and the importance of early detection and treatment. These initiatives are driving the demand for breast cancer therapeutics, as more women are being diagnosed and treated for the disease.

What are the key restraints of the Global Breast Cancer Therapeutics Market?

While the global breast cancer therapeutics market is expected to grow at a significant pace, there are also several key restraints that could potentially slow down the growth of the market, including: High cost of treatments: The cost of breast cancer treatments can be very high, which can be a significant barrier to access for many patients, particularly in low- and middle-income countries. This could limit the growth of the breast cancer therapeutics market in these regions.

Stringent regulatory requirements: The development and approval of new drugs for the treatment of breast cancer is a lengthy and expensive process, with stringent regulatory requirements in place to ensure safety and efficacy. This can slow down the development and approval of new treatments, which could limit the growth of the market.

Side effects of treatments: Breast cancer treatments can have significant side effects, including nausea, fatigue, hair loss, and cognitive impairment. This can limit the use of these treatments, particularly in older or more frail patients, and could impact the growth of the market.

Alternative treatment options: Some patients may choose to explore alternative or complementary therapies for the treatment of breast cancer, which could limit the growth of the breast cancer therapeutics market.

Lack of awareness and access: Despite growing awareness about breast cancer, there are still many regions where women have limited access to healthcare and screening services. This could limit the growth of the breast cancer therapeutics market, as patients may not be diagnosed and treated in a timely manner.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Competitive Landscape

Which are the major players in the Global Breast Cancer Therapeutics Market?

The global breast cancer therapeutics market is highly competitive, with several key players competing for market share. Some of the key players in the market include: AstraZeneca is a British-Swedish multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including hormone therapies, targeted therapies, and chemotherapy drugs.

Roche is a Swiss multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including targeted therapies and chemotherapy drugs.

Pfizer is an American multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including hormone therapies and chemotherapy drugs.

Novartis is a Swiss multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including hormone therapies, targeted therapies, and chemotherapy drugs.

Eli Lilly is an American multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including targeted therapies and chemotherapy drugs.

Other key players in the global breast cancer therapeutics market include Sanofi, Merck, Celgene Corporation, and Johnson & Johnson. These companies invest heavily in research and development to develop new treatments for breast cancer, and they also work to improve patient access to breast cancer treatments by expanding their distribution networks and working with healthcare providers to improve diagnosis and treatment.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

How do breast cancer treatment markets,

healthcare policies, & reimbursement scenarios

vary around the world?

Healthcare Policy and Regulatory Landscape

The healthcare policy and regulatory landscape for breast cancer therapeutics varies across different regions and countries. However, there are some common themes and initiatives that are aimed at improving access to breast cancer treatment and care.

In the US, the Food and Drug Administration (FDA) is responsible for the regulation of drugs and therapies for the treatment of breast cancer. The FDA has established a comprehensive regulatory framework for the development, testing, and approval of new treatments for breast cancer. The agency has also implemented various initiatives aimed at expediting the development and approval of new drugs for serious or life-threatening diseases, including breast cancer. These initiatives are aimed at increasing patient access to new and innovative therapies.

In Europe, the European Medicines Agency (EMA) is responsible for the regulation of drugs and therapies for the treatment of breast cancer. The EMA has established a comprehensive regulatory framework that is aimed at ensuring the safety and efficacy of new treatments for breast cancer. The agency has also implemented various initiatives aimed at improving patient access to new and innovative therapies.

In addition to regulatory agencies, there are also various healthcare policy initiatives and organizations that are working to improve access to breast cancer treatment and care. For example, the World Health Organization (WHO) has established a global breast cancer initiative aimed at improving access to screening, diagnosis, and treatment for breast cancer. The initiative is focused on improving awareness about breast cancer, increasing access to screening and diagnosis, and improving access to quality treatment and care.

Overall, the healthcare policy and regulatory landscape for breast cancer therapeutics is complex and constantly evolving. However, there is a growing focus on improving patient access to innovative and effective treatments, and on improving awareness and education about breast cancer.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

Reimbursement Scenario

Reimbursement for breast cancer therapeutics varies depending on the country and the specific treatment involved. Generally, breast cancer therapeutics reimbursement is typically provided through a combination of public and private health insurance programs.

In the US, reimbursement for breast cancer therapeutics is typically provided through private health insurance plans or public insurance programs such as Medicare and Medicaid. Private health insurance plans typically cover a portion of the cost of breast cancer treatments, but patients may still be responsible for co-payments, deduct-ibles, and other out-of-pocket expenses. Medicare and Medicaid also cover a portion of the cost of breast cancer treatments, but coverage varies depending on the specific treatment and the patient's eligibility.

In Europe, reimbursement for breast cancer therapeutics is typically provided through national healthcare systems.

Coverage and reimbursement policies vary depending on the country, but most national healthcare systems provide coverage for breast cancer treatments. In some countries, patients may be responsible for co-payments or other out-of-pocket expenses.

In other regions, such as Asia and Latin America, reimbursement for breast cancer therapeutics may be provided through a combination of public and private health insurance programs. However, access to healthcare and reimbursement for breast cancer treatments may be limited in some regions due to factors such as cost, lack of infrastructure, and limited healthcare resources.

Overall, reimbursement for breast cancer therapeutics is an important factor in patient access to care. Govern-ments, regulatory agencies, and healthcare organizations are working to improve patient access to effective and affordable breast cancer treatments, including by implementing reimbursement policies that support the use of these treatments.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

What are the latest trends and innovations in

the global breast cancer market?

WHO Launches New Roadmap on Breast Cancer

In February 2023, the World Health Organization (WHO) launched a new Global Breast Cancer Initiative Framework that serves as a road map for achieving the goals of 2.5 Mn lives save from breast cancer by 2040. The new Framework advises nations to put the three health promotion pillars of early detection, prompt diagnosis, and thorough management of breast cancer into practise in order to meet the targets.

In order to develop resource-appropriate, country-specific health systems for the delivery of breast cancer care in low- and middle-income countries, a recently published framework makes use of tried-and-true techniques. With precise critical performance metrics, it specifies three action pillars:

▪

Advising nations to prioritise breast cancer early-detection initiatives so that at least 60% of breast cancer cases are identified and treated in the early stages

▪

Breast cancer outcomes can be improved by receiving a diagnosis within 60 days of the initial appearance. After the initial presentation, treatment should begin within three months

▪

Managing breast cancer should ensure that at least 80% of patients finish the suggested course of treatment 24

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

AI in Breast Cancer

Artificial intelligence (AI) technology has been developed by engineers at the University of Waterloo to determine whether chemotherapy before surgery would be beneficial for people with breast cancer.

Choosing the best course of action for a specific breast cancer patient is currently highly challenging, and it is critical to prevent unwanted side effects from being caused by treatments that are unlikely to actually benefit the patient.

The open-source Cancer-Net initiative's new AI system could help unsuitable candidates avoid the harmful side effects of chemotherapy and improve surgical outcomes for those who are qualified. It is lead by Dr. Alexander Wong.

Conclusion

The breast cancer market has seen significant growth over the past few years, driven by rising awareness of the disease, improved screening and diagnostic technologies, and advancements in treatment options. Additionally, the increasing incidence of breast cancer and the growing aging population have also contributed to the growth of the breast cancer market.

In terms of regional markets, North America and Europe are currently the largest markets for breast cancer products and services. However, emerging markets such as Asia-Pacific and Latin America are expected to grow rapidly in the coming years due to improving healthcare infrastructure, rising disposable incomes, and increasing awareness of breast cancer.

Due to the limited research and development in these particular fields, there are few treatment options and medications available for rare kinds of breast cancer. Patients and healthcare experts who are attempting to manage and treat these forms of breast cancer may find this to be a substantial obstacle.

Inflammatory breast cancer, triple-negative breast cancer, and HER2-positive breast cancer are a few uncommon types of the breast cancer. It is crucial to have access to appropriate treatments because some forms of breast cancer can be more aggressive and challenging to treat than more typical forms.

Overall, the global breast cancer market is expected to continue to grow in the coming years, driven by factors such as rising incidence rates, increasing awareness and screening, and advancements in treatment options. However, the high cost of cancer treatments and the lack of access to quality healthcare in certain regions remain major challenges in the breast cancer market.

Global Breast Cancer Therapeutics Market Analysis, 2022-2030

ABOUT

INSIGHTS10

Insights10 is a healthcare-focused market research firm founded with an aim of being an insights-driven company in the data-driven world and delivering actionable insights that can drive decisions and strategy-making processes for our clients.

It is a market research firm that provides syndicated and customized research reports in healthcare and allied industries such as Pharmaceuticals, Diseases/Therapies, Medical Devices, Digital Health, Healthcare Services, OTC

and Nutraceuticals, etc.

Our qualitative, acute, and result-oriented market research reports provide a comprehensive understanding of the business scenario and the latest trends related to the life sciences market.

Whether you are looking to expand into new areas, develop new products, or take advantage of new opportunities we have reports to help you accelerate and improve your plans by identifying unique growth prospects.

www.insights10.com

References

https://www.cancer.gov/about-cancer/treatment/drugs/breast https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap-on-breast-cancer#:~:text=The%20

World%20Health%20Organization%20(WHO,from%20breast%20cancer%20by%202040

https://theprint.in/science/study-artificial-intelligence-detect-effectiveness-of-breast-cancer-chemotherapy/

1359920/